Investors Asset Management of Georgia Inc. GA ADV Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Investors Asset Management of Georgia Inc. GA ADV decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 24.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,375 shares of the medical research company’s stock after selling 441 shares during the quarter. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Amgen were worth $396,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMGN. OFI Invest Asset Management purchased a new position in Amgen during the 3rd quarter valued at $26,000. Briaud Financial Planning Inc purchased a new position in Amgen during the 3rd quarter valued at $26,000. Strategic Investment Solutions Inc. IL purchased a new position in Amgen during the 1st quarter valued at $28,000. BOK Financial Private Wealth Inc. purchased a new position in Amgen during the 4th quarter valued at $29,000. Finally, Providence Capital Advisors LLC purchased a new position in Amgen during the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. UBS Group decreased their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 price target on shares of Amgen in a research report on Wednesday, April 3rd. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $296.95.

Amgen Stock Performance

Shares of AMGN traded down $0.70 during mid-day trading on Thursday, reaching $263.37. The company had a trading volume of 753,540 shares, compared to its average volume of 2,833,427. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $141.15 billion, a P/E ratio of 21.14, a PEG ratio of 2.47 and a beta of 0.58. The stock has a 50 day moving average of $277.99 and a two-hundred day moving average of $281.37.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the prior year, the business earned $4.09 earnings per share. The company’s revenue was up 19.8% compared to the same quarter last year. On average, analysts expect that Amgen Inc. will post 19.46 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.42%. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.